Adaptimmune Therapeutics ADAPY
OTC ADAPY
$0.02 +0.00 (+0.00%)
At close: Nov 10, 2026 · 4:00 PM EST

Adaptimmune Therapeutics (ADAPY) EBIT (2014 - 2025)

Updated

Adaptimmune Therapeutics (ADAPY) posted EBIT of -$30.29 million for Q2 2025, compared with $68.7 million a year earlier.

Analysis

Adaptimmune Therapeutics (ADAPY) EBIT (2014 - 2025) Analysis & Trends

For the trailing twelve months through Jun 30, 2025, EBIT at Adaptimmune Therapeutics was -$164.22 million; for FY2024, it was -$68.76 million.

  • In prior years, Adaptimmune Therapeutics' EBIT was -$139.74 million in FY2023, -$163.97 million in FY2022, -$162.25 million in FY2021 and -$133.41 million in FY2020.
  • Quarterly EBIT has run from a low of -$73.52 million in Q4 2024 to a high of $68.7 million in Q2 2024 over five years.
  • According to Business Quant data, EBIT for the three prior quarters was -$45.73 million (Q1 2025), -$73.52 million (Q4 2024) and -$14.68 million (Q3 2024).
Peer Set

Peer Comparison

Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -30.29 Mn
Mar 31, 2025 -45.73 Mn
Dec 31, 2024 -73.52 Mn
Sep 30, 2024 -14.68 Mn
Jun 30, 2024 68.70 Mn
Mar 31, 2024 -49.26 Mn
Dec 31, 2023 -49.86 Mn
Sep 30, 2023 -46.63 Mn
Jun 30, 2023 -44.91 Mn
Mar 31, 2023 1.66 Mn
Dec 31, 2022 -27.24 Mn
Sep 30, 2022 -42.99 Mn
Jun 30, 2022 -43.75 Mn
Mar 31, 2022 -49.98 Mn
Dec 31, 2021 -42.86 Mn
Sep 30, 2021 -42.18 Mn
Jun 30, 2021 -39.31 Mn
Mar 31, 2021 -37.89 Mn
Dec 31, 2020 -37.51 Mn
Sep 30, 2020 -35.88 Mn
API Access

Adaptimmune Therapeutics EBIT API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebit&ticker=ADAPY&period=max&api_key=YOUR_API_KEY